Compare Adobe Systems Inc (ADBE) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Biogen Inc — how do they compare? Adobe Systems Inc trades at $256.8 (market cap $104.82B), while Biogen Inc trades at $207.26 (market cap $30.13B). The key difference: Adobe Systems Inc is far larger — about 3.5× Biogen Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | BIIB | |
|---|---|---|
Market Cap | $104.82B | $30.13B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $216.63 |
52-Week Low | $193.41 | $128.93 |
Enterprise Value | $106.26B | $37.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) is trading at $255.80, down 6.29% in the last 24 hours amid broader tech sector volatility. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $5.96 beating expectations of $5.82. Revenue growth remains robust at $23.77B in 2025, with net income margin expanding to 29.99%. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $252.
Adobe presents a compelling value opportunity with a P/E of 15.09 below historical averages, though AI competition and CEO transition risks warrant caution. Analyst consensus remains positive with 49.2% buy ratings and $248.86 price target, suggesting potential upside from current levels despite recent selloff.
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
